Therapeutic approach to lung disease
AssigneesThe Regents of the University of California, Vanderbilt University, The Children's Hospital of Philadelphia
InventorsXin Sun, Jinhao Xu, Lisa Young
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a novel animal model of NEHI, and method of preventing and/or treating a pulmonary disease, particularly the lung-based complications in NEHI, such as pulmonary edema, by targeting the PNEC product, such as the CGRP signaling. Also disclosed is the pharmaceutical composition for preventing and/or treating a pulmonary edema and/or other pulmonary disease, particularly, NEHI, comprising one or more CGRP signaling antagonist and/or inhibitor of the present disclosure.
Claims10
A method of treating a pulmonary edema in a patient comprising administering to the patient a therapeutically effective amount of a CGRP signaling antagonist selected from the group consisting of olcegepant (BIBN4096BS), telcagepant (MK-0974), rimegepant (BMS-927711), BI 44370 TA, MK-3207, ubrogepant (MK-1602), and MK-8031.
A pharmaceutical composition for treating a pulmonary edema in a patient in need thereof, comprising a therapeutically effective amount of one or more CGRP signaling antagonists selected from the group consisting of olcegepant (BIBN4096BS), telcagepant (MK-0974), rimegepant (BMS-927711), BI 44370 TA, MK-3207, ubrogepant (MK-1602), and MK-8031.
Dependencies are inferred from the claim text.